GIC Invests in Hua Medicine
Posted on 03/27/2018
Shanghai-based Hua Medicine raised a combined US$ 117.4 million in Series D & Series E rounds. Hua Medicine is a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes. The new investors in these rounds include Blue Pool Capital Limited, GIC Private Limited, AVICT Global, 6 Dimensions Capital, Adrian Cheng […]
